Development of novel theranostics radiopharmaceuticals

We managed to obtain regulatory approval for novel diagnostic radiopharmaceutical ([111In]In-CP04) for personalized diagnosis and therapy of patients with medullary thyroid carcinoma(H2020 GRAN-T-MTC, JTC-TRANSCAN 643638 grants). We found out that 18F-fluorocholine PET/CT imaging was effective for preoperative localization of hyperfunctioning parathyroid tissue. We verified the dosimetry and binding potential of 99mTc-based somatostatin antagonist in murine models(TECANT, ERAPERMED2018-125 grants). We assessed the efficacy and safety of ultrasonographically (US)-guided high-intensity focused ultrasound (HIFU) ablation to treat benign solid thyroid nodules. We also identified the importance of monitoring the iodine supply to prevent iodine deficiency disorders (EUthyroid, H2020 634453 grant).